The present invention provides a nitrilase mutant and application thereof in the synthesis of 1-cyanocyclohexyl acetic acid, the nitrilase mutant is obtained by mutating one or two of the amino acids at position 180 and 205 of the amino acid sequence shown in SEQ ID No. 2. In the present invention, by semi-rational design and protein molecular modification, the specific enzyme activity of the nitrilase double mutant AcN-G180D/A205C was increased by up to 1.6 folds, and the conversion rate>99%. And the reaction time was shortened to a quarter of the original using the recombinant Escherichia coli containing the nitrilase mutant to hydrolyze 1-cyanocyclohexylacetonitrile at high temperature (50° C.). Therefore, the mutants obtained by the present invention have a good application prospect in efficiently catalyzing 1-cyanocyclohexylacetonitrile to synthesize gabapentin intermediate, 1-cyanocyclohexyl acetic acid.

The present invention belongs to the field of microbiology, and particularly relates to an application of a Pseudomonas aeruginosa vaccine in prevention and treatment of burn and scald complicated with bacterial infection. The burn and scald of the present invention include burns and scalds, and degree of the scalds includes I degree, superficial II degree, deep II degree, or III degree scalds. Site of the scalds includes skin, mucosa or other tissues. The Pseudomonas aeruginosa vaccine of the present invention can effectively prevent and treat burn and scald complicated with Pseudomonas aeruginosa infection caused by multidrug-resistant Pseudomonas aeruginosa by activating the specific immune response of the body. The Pseudomonas aeruginosa vaccine of the present invention can reduce the bacterial load in the immunized subject through the established immunization procedures, thereby providing a technical solution that can effectively prevent burn and scald complicated with Pseudomonas aeruginosa infection, which avoids the technical problems caused by the use of antibiotics such as poor effectiveness, difficulty in curing and proneness to drug resistance in the prior art to a certain degree.

In an aspect, the present disclosure provides a novel microorganism having an ester degrading ability. In an aspect, the present disclosure provides a combination of novel microorganisms having an oil degrading ability. In an embodiment, the microorganism of the present invention includes a yeast belonging to the genus Yarrowia. In an embodiment, the microorganism of the present invention includes Yarrowia lipolytica. In an embodiment, the present disclosure provides a combination of a Burkholderia bacterium with a Yarrowia yeast. In an embodiment, provided is an oil degrading agent that comprises the microorganism of the present disclosure.

This invention provides compositions and methods for providing high product yield of transgenes encoding biopharmaceutical polypeptides in cyanobacteria and microalgae.

Provided herein are compounds of Formula A, methods for the preparation thereof, and uses thereof for treating or preventing bacterial infections.

##STR00001##

The present invention generally relates to a system and process for producing a biosurfactant, and more particularly to a system and process for producing a biosurfactant from at least one strain of Bacillus subtilis, and formulations which comprise the biosurfactant.

The invention relates to a metabolic enzyme-disrupted aerobic strain and a method for culturing the strain. The present invention provides, for example, a culture comprising a culture medium that has been cultured under an aerobic condition, wherein the culture medium contains an aerobe, wherein the aerobe has a disrupted gene encoding a metabolic enzyme of glycolysis selected from the group consisting of the metabolic enzymes of glycolysis except hexokinase, thereby suppressing metabolism from a carbon source (e.g., glucose) to the TCA cycle in the aerobe.

Disclosed is a mutant strain having improved aromatic amino acid production capability as a result of the inactivation or weakening of activity of asparaginase which is expressed by ansB gene.

The present invention relates to a novel Lactobacillus plantarum IMB19 strain, polysaccharides derived from the strain, and a use thereof. A novel Lactobacillus plantarum IMB19 strain and polysaccharides derived from the strain of the present invention exhibit an excellent CD8+T cell activity stimulating ability and Treg cell inhibitory activity, and stimulate and improve an antitumor immune response through various mechanisms such as increased macrophage infiltration in CPS tumors and differentiation and reprogramming of macrophages into an inflammatory phenotype (M1). Therefore, a strain and polysaccharides derived from the strain of the present invention can be effectively used for immune regulation, especially immune boosting, in a subject, and can inhibit tumor growth by inducing and enhancing an antitumor immune response. A novel strain and polysaccharides derived from the strain of the present invention are useful in the prevention, alleviation or treatment of such as tumors, infectious diseases and various immune diseases that are the cause of or symptom of immune dysfunction.

The disclosure relates to a Lactobacillus plantarum HG-23 and application thereof. The Lactobacillus plantarum HG-23 has been deposited with the China Center for Type Culture Collection as assigned Accession Number CCTCC No.: M2021330. The Lactobacillus plantarum HG-23 of the disclosure can be used for preparing hypolipidemic food or hypolipidemic drugs. The Lactobacillus plantarum HG-23 screened in the disclosure is good in safety, can tolerate gastric acid and bile salts, and survives and colonizes in intestinal tract to regulate and improve the intestinal microecological balance of a host, so as to play a beneficial effect and generate an exact healthy effect; in-vitro and animal tests show that the Lactobacillus plantarum HG-23 has a strong function of reducing triglyceride and cholesterol in blood.